ABSTRACT

A wide range of genetic mouse models is available to help researchers dissect human disease mechanisms. Each type of model has its own distinctive characteristics arising from the nature of the introduced mutation, as well as from the specific changes to the gene of interest. Here, we review the current range of mouse models with mutations in genes causative for the human neurodegenerative disease amyotrophic lateral sclerosis. We focus on the two main types of available mutants: transgenic mice and those that express mutant genes at physiological levels from gene targeting or from chemical mutagenesis. We compare the phenotypes for genes in which the two classes of model exist, to illustrate what they can teach us about different aspects of the disease, noting that informative models may not necessarily mimic the full trajectory of the human condition. Transgenic models can greatly overexpress mutant or wild-type proteins, giving us insight into protein deposition mechanisms, whereas models expressing mutant genes at physiological levels may develop slowly progressing phenotypes but illustrate early-stage disease processes. Although no mouse models fully recapitulate the human condition, almost all help researchers to understand normal and abnormal biological processes, providing that the individual characteristics of each model type, and how these may affect the interpretation of the data generated from each model, are considered and appreciated.

KEY WORDS: Amyotrophic lateral sclerosis, ALS, Transgenic, Knock-in, ENU, Gene targeted

Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder first described in 1869 by Jean-Martin Charcot (Charcot and Joffrey, 1869). It has a mean incidence of ∼2/100,000 worldwide and a prevalence of ∼6/100,000 in Europe (Costa and de Carvalho, 2016; Marin et al., 2016), with a lifetime risk of ∼1 in 300 in Western populations (Brown and Al-Chalabi, 2017). ALS patients typically present a focal onset, starting as unilateral limb weakness or bulbar impairment. Clinical symptoms usually start in mid-life and are a consequence of the dysfunction and death of motor neurons (MNs) in the primary motor cortex, brainstem and spinal cord, which causes spasticity, weakness and muscle wasting, gradually leading to paralysis and death from respiratory failure, typically less than 5 years from diagnosis (Huynh et al., 2016; Van Damme et al., 2017).

There are no effective treatments for ALS apart from daily care and support to counteract the symptoms. Currently, there are only two US Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved neuroprotective drugs that increase the lifespan of some patients by a few months: Riluzole, which blocks excessive glutamatergic neurotransmission, and Edaravone, which prevents oxidative stress damage.

Although 90% of ALS patients have sporadic (sALS) disease without apparent family history, ∼5-10% of cases are familial (fALS), usually showing monogenic autosomal dominant inheritance (Brown and Al-Chalabi, 2017). In 1993, the first causative gene for ALS was discovered, encoding the enzyme Cu/Zn superoxide dismutase 1 (SOD1) (Rosen et al., 1993). Research shows that SOD1-ALS accounts for ∼20% of fALS and ∼2% of sALS, with >150 mutations identified throughout the coding region and causing an unknown toxic gain of function (GOF) (Saccon et al., 2013; Kaur et al., 2016). SOD1 is ubiquitously expressed and important for the removal of free radicals, although it likely has other non-canonical roles; for example, as a transcriptional regulator under oxidative stress, possibly as an RNA-binding protein and a signalling molecule (Bunton-Stasyshyn et al., 2015).

Since the discovery of SOD1’s association with ALS, mutations in more than 20 genes were found to be causative, most with an autosomal-dominant pattern of transmission, together with >30 potential disease-modifying genes (Li and Wu, 2016). Causative genes include the chromosome 9 open reading frame 72 (C9ORF72), in which an intronic hexanucleotide repeat expansion gives rise to ALS. This mutation is the most common cause of fALS, and is found in up to 40% of fALS and ∼9% of sALS in Caucasians (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Goldstein et al., 2018). Other well known 'ALS genes' include TAR DNA-binding protein (TARDBP; encoding TDP-43), found in ∼5% of fALS and ∼2% of sALS, and fused in sarcoma (also known as FUS RNA-binding protein; FUS), found in ∼6% of fALS and ∼1% of sALS (Ingre et al., 2015; Tararini et al., 2015). TDP-43 and FUS are RNA-binding heterogeneous nuclear ribonucleoproteins (hnRNPs) mainly localised in the nucleus, and are involved in mRNA splicing, gene transcription and microRNA maturation, mRNA shutting from the nucleus to the cytoplasm and stress granule formation. Cytoplasmic mislocalisation and nuclear depletion of TDP-43 is a key feature of most ALS cases and may contribute to disease pathogenesis (Guerrero et al., 2016). Protein aggregates containing truncated hyperphosphorylated and/or ubiquitinated TDP-43 are found within MNs in >95% of ALS-affected brains and spinal cords (Chou et al., 2018), and can occur in other neurological disorders, including Alzheimer’s, Parkinson’s and Huntington’s diseases, highlighting...
the importance of TDP-43 in neurodegeneration (Liu et al., 2017; St-Amour et al., 2018).

Other genes less frequently mutated in ALS include coiled-coil-helix-coiled-coil-helix domain-containing 10 (CHCHD10) (Bannwarth et al., 2014), kinesin family member 5A (KIF5A) (Brenner et al., 2018), matrin 3 (MATR3) (Johnson et al., 2014), optineurin (OPTN) (Maruyama et al., 2010), profilin 1 (PFN1) (Wu et al., 2012), senataxin (SETX) (Chen et al., 2004), sequestosome 1 (SQSTM1/p62) (Fecto, 2011), TANK-binding kinase 1 (TBK1) (Cirulli et al., 2015; Freischmidt et al., 2015), ubiquilin 2 (UBQLN2) (Deng et al., 2011), valosin-containing protein (VCP) (Johnson et al., 2010) and VAMP-associated protein B and C (VAPB) (Nishimura et al., 2004). As each new gene is identified, the next step is to make a mouse model. There are different types of mutant mice, which yield different insights and should be used to address different research questions.

Mouse models of ALS

We know little of early-stage ALS pathomechanisms, and we still have a lot to learn about the disease trajectories for fALS and sALS. Here, we discuss the main features of the different types of mouse models that are helping us to elucidate the molecular pathology of ALS and its phenotypic implications: transgenic mice, and targeted and ENU mutant mice (Fig. 1). We then focus on comparing the phenotypes of mice with ALS gene mutations for which at least two of these types of model have been published; namely, FUS, SOD1, TARDBP, VAPB, VCP and UBQLN2.

Transgenic mouse models

ALS is mostly an autosomal-dominant disorder and therefore the majority of mouse models have been transgenic lines, made by randomly inserting human (in most cases) mutant ALS genes into the mouse genome (Table 1). This is a fast method of producing new strains and, because the disease is dominant, the phenotype usually manifests, despite the presence of intact orthologous mouse genes. Indeed, the first model of ALS, the SOD1G93A transgenic strain [Tg(SOD1*G93A)1Gur], was published a year after the discovery of SOD1-ALS mutations in humans (Gurney et al., 1994) (Table 1A) and remains the most commonly used ALS mouse model. Owing to the early onset, fast disease progression towards an early humane endpoint, progressive MN loss and low variability of the phenotype on defined genetic backgrounds, the SOD1G93A transgenic strain has become the workhorse for testing therapeutics aimed at ameliorating ALS.

Around 30 FUS and TARDBP mutant transgenic lines have also been created, with variable levels of MN degeneration (Table 1B,C).

![Fig. 1. Features of transgenic versus physiological mouse models for studying ALS. Examples from Table 1, showing potential windows of ALS pathology to investigate using transgenic or physiological mouse models; lengths of arrows correspond, approximately, to the severity of the phenotype on either heterozygous or homozygous mice at the oldest age measured, as per the references. We note that with respect to ALS genetic models, the SOD1 G93A (Gurney et al., 1994) mouse was the first transgenic line. We believe that Vcp R155H (Badadani et al., 2010; Yin et al., 2012) was the first gene-targeted model, the Sod1 D83G (Joyce et al., 2015) line was the first ENU mouse model, and the FUSDelta14 model (Devoy et al., 2017) was the first genomically humanised knock-in to the endogenous mouse locus, although this is a partial humanisation; see Table 1.](image-url)
### Table 1. Mouse models of ALS for which both transgenic and knock-in strains are published

| Strain name | Transgenic/gene-targeted knock-in | Genetic background | Protein | Inclusions/aggregates | Glialosis | MA/MD | NMJ loss | Final-stage disease (terminal MN loss) | Survival (weeks) | Behavioural analysis | Other phenotypes | Reference |
|-------------|-----------------------------------|--------------------|---------|-----------------------|-----------|----|---------|---------------------------------|-----------------|-------------------|----------------|----------|
| **(A) SOD1 mouse models** | | | | | | | | | | | | | |
| WT SOD1 (JAX 002297) | Transgenic | C57BL/6SJ L | High hSOD1 expression with increased enzyme activity | Ubiquitin: P | P | Mild | ND | Earlier signs: 30-50 weeks; MN loss: 20-30% at ∼104 weeks | 75-104 | Mild motor coordination impairment | Argyrophilic fibre degeneration in SC. | (Gurney et al., 1994; Jaarna et al., 2000) |
| WT SOD1 | Transgenic | C57BL/6CSB | hSOD1 expressed > 90% higher than endogenous SOD1 but with low enzyme activity | Inclusions: P | ND | ND | ND | Earlier signs: ∼36 weeks; ∼52 weeks | 41% at late stage | Mild motor coordination impairment | Heavy vacuolisation in subcortical, weight loss, loss of Purkinje cells. | (Graffito et al., 2013) |
| SOD1A4V | Transgenic | C57BL/6SJ L | hSOD1; low expression levels with no-enzyme activity | Ab | Ab | Ab | Ab | Ab | Normal | ND | | | | |
| SOD1 G37R (JAX 08342) | Transgenic | C57BL/6SJ J | hSOD1; low expression | Inclusions: P | ND | ND | ND | Earlier signs: 52 weeks; MN loss: % | 25-29 | Motor coordination impairment and cognitive impairment | Develop rigid thoracolumbar kyphosis. | (Wong et al., 1995; Fild et al., 2011) |
| SOD1 G37R | Transgenic | JAX 002297 | | Inclusions: P | ND | ND | ND | Ab/normal | Normal | | | | |
| SOD1 G46R | Transgenic | C57BL/6SJ L | hSOD1; high expression but inactive protein | Inclusions: P | P | ND | ND | Earlier signs: 20 weeks; MN loss: % | 24 | Motor coordination impairment | Body weight loss. | (Chang-Hong et al., 2005) |
| SOD1 H46R/H48Q | Transgenic | C3H/Jc57BL/6 J | hSOD1; high expression but inactive protein | Inclusions: P | P | ND | ND | Earlier signs: 17-26 weeks; MN loss: %; end-stage paralysis: ∼21 weeks | 44-52 | Motor coordination impairment | | (Wang et al., 2002) |
| SOD1 H46R/H48Q/ | Transgenic | C3H/Jc57BL/6 J | hSOD1; high expression but inactive protein | Inclusions: P | P | P | ND | Earlier signs: 21-26 weeks; no final MN loss | 26-30 | Motor coordination impairment | | (Todisawa et al., 2003) |
| H80G/H100G | Transgenic | | | P | P | P | P | P | P | Progressive motor coordination impairment | | (Brajin et al., 1997) |
| SOD1 L45V | Transgenic | C57BL/6 SJ | hSOD1; high expression but low metabolic stability | Ab | Ab | Ab | Ab | Normal | | | | | | |
| SOD1 G58R (JAX 09248) | Transgenic | | | P | ND | ND | ND | Earlier signs: 44-48 weeks; MN loss: %; end-stage paralysis: ∼34-52 weeks | 50-54 | Progressive motor coordination impairment | | (Wang et al., 2009) |
| SOD1 G58R (JAX 09248) | Transgenic | | | P | ND | ND | ND | Earlier signs: 26-35 weeks; MN loss: %; end-stage paralysis: 2 weeks after initial signs | | Progressive motor coordination impairment | | (Wang et al., 2009) |
| SOD1 H46R/H48Q/ | Transgenic | | | | | | | | | | | | |
| H80G/H100G | Transgenic | | | | | | | | | | | | |
| SOD1 G93A (JAX 002736) | Transgenic | C57BL/6 SJ | hSOD1; high expression | Inclusions: P | P | P | P | Earlier signs: 13-17 weeks; MN loss: %; end-stage paralysis: ∼19 weeks | 13-26 | Motor coordination impairment | Females survive longer than males. Anxiety-like behaviour, alterations in spatial navigation learning and memory. | (Gurney et al., 1994; Tur et al., 1996; Dang et al., 2006; Quarl et al., 2015) |
| SOD1 H46R/H48Q/ | Transgenic | | | | | | | | | | | | |
| H80G/H100G | Transgenic | | | | | | | | | | | | |
| SOD1 G93A (JAX 002736) | Transgenic | C57BL/6 SJ | hSOD1; high expression | Inclusions: P | P | P | P | Earlier signs: >70 weeks; no final MN loss | >70 | Normal | Astrocytic morphology changes. | (Wong et al., 1995) |
| SOD1 G93A (JAX 002736) | Transgenic | C57BL/6 SJ | hSOD1; high expression | Inclusions: P | P | P | P | Earlier signs: 52 weeks; 40% loss of ventral horn neurons; disease duration: 50 days | 61 | Motor coordination impairment | HOMs: distended bladder (resembling HOM D90A patients) and vacuoles throughout ventral neural. Age-dependent phenotype in HEM. | (Jonsson et al., 2006) |
Table 1. Continued

| Strain name | Transgenic/gene- targeted knock-in/ENU | Genetic background | Protein | Inclusions/aggregates | Gliosis | MA/MD | NMJ loss | Final-stage disease (terminal MN loss) | Survival (weeks) | Behavioural analysis | Other phenotypes | Reference |
|-------------|----------------------------------------|--------------------|---------|-----------------------|---------|-------|---------|----------------------------------------|----------------|----------------------|-----------------|-----------|
| SOD1 G93A (JAX 02330) | Transgenic; Promoter: hSOD1 | C57BL/6.S(Jax) | hSOD1; lower expression | Inclusions: P | P | P | Earlier signs: 24-36 weeks; MN loss: >50%; end-stage paralysis: at 29-39 weeks | 29-39 | Motor coordination impairment. Low copy Gurney G93A line | Females survive longer than males. | (Gurney et al., 1994; Alexander et al., 2004; Jaarna et al., 2000) |
| SOD1 Thy1.2-G93A (JAX 008230) | Transgenic; Promoter: Thy 1.2 | C57BL/6J | hSOD1; low expression | Inclusions: P | P | P | Earlier signs: 4-10 weeks; MN loss: >40% | 62-104 | Motor coordination impairment | Non-focal onset. | (Lino et al., 2002) |
| SOD1 G93A line | | | | | | | | | | | |
| SOD1 G93A | Promoter: hSOD1 | C57BL/6.B6; low expression | Inclusions: P | P | P | Earlier signs: 35 weeks; MN loss: >50%; end-stage paralysis: at 28-36 weeks | 36 | Motor coordination impairment | ND | | |
| SOD1 L126Z | Promoter: hSOD1 | C3H/HeJ-C57BL/6J | hSOD1; low expression and no activity | Inclusions: P | ND | ND | Earlier signs: 25-43 weeks; MN loss: >50%; end-stage paralysis: at 29-39 weeks | 26-46 | Motor coordination impairment | ND | | |
| SOD1 L126ZdelTT | Promoter: hSOD1 | C57BL/6 | hSOD1; low expression | Inclusions: P | P | SC | Earlier signs: 41 weeks; MN loss: >50%; end-stage paralysis: at 43 weeks | 51-57 | Motor coordination impairment | ND | | |
| SOD1 T116X | Promoter: hSOD1 | C57BL/6×SJL | hSOD1; low expression | Inclusions: P | P | P | Earlier signs: 50 weeks; MN loss: >50%; end-stage paralysis: P | ~104 | Motor coordination impairment | HEMs: no phenotype; HOMs: reported to develop ALS.Double transgenics(T116x/WT hSOD1) develop ALS phenotype; reduced hTDP-43+25-KDa fragments | (Han-Xiang et al., 2010) |
| SOD1 D83G (JAX 012836) | Promoter: mSOD1 | C57BL/6 | hSOD1 | Inclusions: P | P | P | Earlier signs: 15 weeks; UMN loss: >20% by 29 weeks; MN loss: >23% by week 15-52 | ~88 | Motor coordination impairment | Hom: males have significantly reduced lifespan compared with that of females. | (Joyce et al., 2015) |
| SOD1 D83G (JAX 008230) | Transgenic; Promoter: mThy1.2 | C57BL/6 | mSOD1; reduced protein levels and loss of activity | Ab | P | P | Earlier signs at 3 weeks; no Mn loss | ~48 | Mild motor coordination impairment | HOMs show severe motor deficits, brainatrophy and weight loss. | (Xu et al., 2010) |
| SOD1 D83G (JAX 016608) | | | | | | | | | | | |
| SOD1 D83G (JAX 016201) | | | | | | | | | | | |
| SOD1 D83G (JAX 017907) | | | | | | | | | | | |
| SOD1 D83G (JAX 012836) | | | | | | | | | | | |
| SOD1 TDP-43 mouse models | | | | | | | | | | | |
| hTDP-43 WT (JAX 016608) | Transgenic; Promoter: mPrp | C57BL/6 | hTDP-43 and <WT hTDP-43, cytosolic–25–35 kDa fragments | Inclusions: P | P | Ab | Earlier signs at 3 weeks; no Mn loss | ~48 | Motor coordination impairment | Some founders show aggressive motor phenotype (survival of 1-5 weeks). Later-onset lines show weakness and hypotonia. Weight loss. | (Scott et al., 2010) |
| hTDP-43 WT lines 3, 4, 21 (JAX 016201) | | | | | | | | | | | |
| hTDP-43 WT (JAX 017907) | Transgenic; Promoter: mPrp | C57BL/6 | No nuclear loss of hTDP-43; expression decrease of endogenous protein | Ab | Ab | No final Mn loss | ~104 | Motor coordination impairment | HOMs: no phenotype; HOMs: no weight loss. | (Arnold et al., 2013; Mitchell et al., 2015) |
| hTDP-43 WT line W3 | Transgenic; Promoter: mThy1.2 | C57BL/6 | hTDP-43 nuclear inclusions containing FUS, SC35 (also known as SRSF2) and proteins involved in DNA metabolism | Ab | P | P | Earlier signs at 2–12 weeks; no Mn loss | Normal | Motor coordination impairment | Phenotype has more severe in males than females. Significant increase in GEM bodies in Mn. | (Shan et al., 2010) |
| hTDP-43 WT (JAX 012836) | Transgenic; Promoter: mThy1.2 | C57BL/6; S(Jax) | hTDP-43 | Inclusions: P | P | P | Earlier signs at 2–5 weeks; significant Mn loss in line TAR6/6 and 25% Mn loss in line TAR4/4; end-stage paralysis: P | HOM – 3 HEM – 104 | Motor coordination impairment | Progression of motor impairments with fuscillation and spasms of facial muscle. Differences in the phenotype between Tg lines. | (Wills et al., 2010) |
| Transgenic line | Promoter | Strain(s) | Allele(s) | Inclusions | Ubiquitin | Ab | ND | MN loss | % MN loss | lifespan | Phenotype |
|----------------|----------|-----------|-----------|------------|-----------|---|---|--------|----------|---------|-----------|
| hTDP-43 WT | mTardbp | C3H/C57BL/6 | 25-35 kDa | hTDP-43; increased level of cytoplasmic C-terminal fragment of hTDP-43 | P | ND | P | Early sign at 4-26 weeks; no final MN loss | ND | 25 kDa | Motor coordination impairment |
| TDP-43 A315T/G348C | mPrp | C3H/C57BL/6 | 35 kDa | High hTDP-43+25-35 kDa fragments | P | ND | P | Early signs at 2-8 weeks; no final MN loss | ND | 25 kDa | Motor coordination impairment |
| TDP-43 M337V | mPrp | C57BL/6/C3H | 35 kDa | hTDP-43+25-35 kDa fragments | P | ND | ND | No final MN loss | 25 kDa | Motor coordination impairment |
| hTDP-43 M337V | mPrp | C57BL/6 | 25 kDa | hTDP-43+25-35 kDa fragments | P | ND | ND | No final MN loss | 25 kDa | Motor coordination impairment |
| TDP-43 M337V | mTardbp | C57BL/6 | 25 kDa | hTDP-43+25-35 kDa fragments | P | ND | ND | No final MN loss | 25 kDa | Motor coordination impairment |
| TDP-43 M337V | mPrp | C57BL/6 | 25 kDa | hTDP-43+25-35 kDa fragments | P | ND | ND | No final MN loss | 25 kDa | Motor coordination impairment |

Mild to no motor coordination impairment

Brain atrophy. Single Tgs express till to no hTDP-43. Degeneration of neurons in DG.

Learning and memory defects. Disruption ERK phosphorylation, inhibition GABA neurotransmitter.

Two mouse lines: TDP-43 WT (expressing TDP-43) show aggressive phenotype in early development stages. dTDP-43 WT on Dox up to 21 days show longer lifespan and slower progressive neurodegeneration.

Peripherin aggregates in the hippocampus. Age-associated cognitive and motor deficits.

Original line on a non-congenic genetic background showed considerable neuromuscular deficits. Hatzipetros et al. (2014) backcrossed the line with C57BL/6J before starting the study. Motor phenotype confounded by gut phenotype. Significant sex differences.

Transgenic founders show aggressive motor phenotype.

HEMs: no phenotype. HOMs: early signs at 40 weeks with brain atrophy and hyperphosphorylated Tau in-cytoplasmin. Weight loss.

Sporadic founders with aggressive phenotype. Founders with milder phenotype show later-onset and longer survival. Weight loss. 
### Table 1. Continued

| Strain name | Transgenic/gene-targeted knock-in/ENU | Genetic background | Protein | Inclusions/aggregates | Glia loss | MA/MD | NMJ loss | Final-stage disease (terminal MN loss) | Survival (weeks) | Behavioural analysis | Other phenotypes | Reference |
|-------------|--------------------------------------|-------------------|---------|------------------------|-----------|-------|---------|----------------------------------------|-----------------|----------------------|-----------------|-----------|
| hTDP-43 Q331K (JAX 017933) | Transgenic | Promoter: mRFP | C57BL6C3H backcrossed with C57BL6/J | No nuclear loss of TDP-43 | Ab | P | P | Early signs at 12 weeks; LMN loss; ~35-40% at 52 weeks | Normal | Motor coordination impairment | Motor deficits and muscle fibrillation. Misregulated cassease exons due to mutated TDP-43. | (Arnold et al., 2013) |
| hTDP-43 Q331K low (JAX 017930) | Transgenic | Promoter: mRFP | C57BL6C3H backcrossed with C57BL6/J | hTDP-43; no nuclear loss of TDP-43 | Ab | P | P | Early signs at 40 weeks; LMN loss; ~35-40% at 52 weeks | ND | Motor coordination impairment | Motor deficits and muscle fibrillation. Misregulated cassease exons due to mutated TDP-43. | (Arnold et al., 2013) |
| TDP-43 Q331K (JAX 030157) | Transgenic | Promoter: mRFP | C57BL6C3H | Nuclear loss of TDP-43. Q331K-TDP-43 mutation appears to have more tendency to aggregate in the cytoplasm | Inclusions: P Ubiquitin: P TDP-43: endogenous | P | P | HOM | Early signs at 3 weeks; MN loss; ~70% in WT xQ331K; end-stage paralysis by 8-10 weeks | 8-10 | Motor coordination impairment | | |
| TDP-43 NLS (JAX 01450) | Transgenic | Promoter: CaMKII | C57BL6J×C3H/HeJ hTDP-43; dramatic loss | Ab | Ab | ND | Early signs at 1-3 weeks off Dox; no final MN loss | ~24 | Motor coordination impairment | | |
| NEFH-tTA (JAX 028412) | Transgenic | Promoter: mPrp | C57BL6/129S2/129P2 | Presence of cytoplasmic hTDP-43 is Dox dependent. Not found when crossed with hTDP-43 WT | Inclusions: P Ubiquitin: P TDP-43: low but co-localises with Ub | P | P | P | Early signs at ≥2 weeks off Dox; MN loss: ≥50% by 6 weeks off Dox | Survival ≥8-18 weeks off Dox and up to 20-32 weeks when Dox reintroduced | Motor coordination impairment | | |
| TDP-43 WT | Human genomic sequence targeted into Rosa26 | C57BL6J×C57BL6/J | hTDP-43 expression lower than endogenous mTDP-43 | Ab | Ab | Ab | Ab | WT comparable with Ntg | Normal | Indistinguishable from Ntg | ND | (Gordon et al., 2019) |
| hTDP-43 A315T | Gene-targeted knock-in | mTardbp | 129S1/129P2/ Ola×C57BL/J | Human cDNA gene targeted into mouse Tardbp locus; alteration of 3' UTR aligning importance for autoregulation | Inclusions: P Ubiquitin: P TDP-43: co-localises with Ub p62: Ab | ND | Ab | ND | Early signs at ~12-20 weeks; MN loss; ~65% at 65 weeks | Normal | Mild motor coordination impairment | Pre-symptomatic model. Reduction of CD36. Altered expression of genes involved in cell death and lipid metabolism. | (Stibit et al., 2014) |
| TDP-43 M337V | Human genomic sequence targeted into Rosa26 | C57BL6/129S2/129P2 | hTDP-43 expression lower than endogenous mTDP-43 | Ab | Ab | P | HOM: early signs at ~26 weeks; symptomatic mice at ~39 weeks; no final MN loss | Normal | Motor coordination impairment | Weight reduction in male HOM. Cytoplasmic mislocalisation of hTDP-43 observed in embryonic stem cell-derived MNs. | (Gordon et al., 2019) |
| Tardbp Q331K (JAX 031345) | Gene-targeted knock-in | mTardbp | C57BL6J | mTDP-43; TDP-43 GOF. 45% increase in nuclear TDP-43 in mutant, impaired autoregulation | Ab | Ab | Ab | Ab | Early signs at ~20 weeks; no final MN loss | ~80 | Mild to no motor coordination impairment in 20 and 24 weeks. Cognitive and memory impairment | Alterant behaviour, hyperphagia, high weight. Phenotypic heterogeneity. Significant expression/ splicing differences in brain, SC by 20 weeks. | (White et al., 2018) |
| Tardbp Q331K | Gene-targeted knock-in | mTardbp | C57BL6J | mTDP-43; TDP-43 gain-of-splicing function | ND | ND | ND | ND | ND | ND | ND | | (Fratta et al., 2018) |
| Strain name | Transgenic/gene-targeted knock-in/ENU | Genetic background | Protein | Inductions/aggregates | Gliosis | MA/MD | NMJ loss | Final-stage disease (terminal MN loss) | Survival (weeks) | Behavioural analysis | Other phenotypes | Reference |
|------------|------------------------------------|-------------------|---------|-----------------------|---------|-------|---------|-----------------------------|-----------------|----------------|----------------|-----------|
| ΔNLS-hFUS (myc-tagged) | Transgenic | | | | | | | | | | | |
| Fus-JNLs/ +Fus-NLs/SNLs | Gene targeted | C57BL/6J | | | | | | | | | | |
| IFO F00N/FUS-P52SL | Gene targeted into the MyF locus | Ola×129/C57BL/6J | | | | | | | | | | |
| IFO F00N/FUS-P521C | Gene targeted into the MyF locus | Ola×129/C57BL/6J | | | | | | | | | | |
| FUSΔΔ14 (EMMA EM-11106) | Gene targeted and partial humanisation | C57BL/6NC57BL/6J | | | | | | | | | | |
| UBOQLN2 mouse models | | | | | | | | | | | |
| UBOQLN2 WT line 358 | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |
| UBOQLN2 WT line 396 (JAX 023870) | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |
| UBOQLN2 P497H | Transgenic | C57BL/6×SJL cross | | | | | | | | | | |
| UBOQLN2 P497S_3/P506T_6 (JAX 029970) | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |

**Table 1. Continued**

| Strain name | Transgenic/gene-targeted knock-in/ENU | Genetic background | Protein | Inductions/aggregates | Gliosis | MA/MD | NMJ loss | Final-stage disease (terminal MN loss) | Survival (weeks) | Behavioural analysis | Other phenotypes | Reference |
|------------|------------------------------------|-------------------|---------|-----------------------|---------|-------|---------|-----------------------------|-----------------|----------------|----------------|-----------|
| UBOQLN2 WT line 358 | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |
| UBOQLN2 WT line 396 (JAX 023870) | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |
| UBOQLN2 P497H | Transgenic | C57BL/6×SJL cross | | | | | | | | | | |
| UBOQLN2 P497S_3/P506T_6 (JAX 029970) | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |

**Table 1. Continued**

| Strain name | Transgenic/gene-targeted knock-in/ENU | Genetic background | Protein | Inductions/aggregates | Gliosis | MA/MD | NMJ loss | Final-stage disease (terminal MN loss) | Survival (weeks) | Behavioural analysis | Other phenotypes | Reference |
|------------|------------------------------------|-------------------|---------|-----------------------|---------|-------|---------|-----------------------------|-----------------|----------------|----------------|-----------|
| UBOQLN2 WT line 358 | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |
| UBOQLN2 WT line 396 (JAX 023870) | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |
| UBOQLN2 P497H | Transgenic | C57BL/6×SJL cross | | | | | | | | | | |
| UBOQLN2 P497S_3/P506T_6 (JAX 029970) | Transgenic | C57BL/6C3/C57BL/6J | | | | | | | | | | |
| UBE2N2 P520T | Gene targeted | C57BL/6j Tac | mUB2N2: observed reduced binding of mutant UBE2N2 to HSP70 | Inclusions: P | Ubiquitin: P | ND | ND | ND | Earlier signs: ~39 weeks; no final MN loss | Cognitive but no motor coordination impairment. |
|--------------|--------------|--------------|------------------------------------------------------------|--------------|--------------|---|---|---|---------------------------------------------|-----------------------------------------------|

| (E) VAPB mouse models |
|-----------------------|
| HAPB WT | Transgenic (with IRES-EGFP reporter doped after STOP codon WAPB) | C57BL/6j-C57BL/6j | HAPB; increased expression | Ab | ND | ND | ND | No final MN loss | Normal |
| HAPB P56S | Transgenic (with IRES-EGFP reporter doped after STOP codon WAPB) | Promoter: mthy 1.2 | HAPB; increased expression but significantly less protein compared with HAPB WT | P520T | ND | ND | ND | Earlier signs: ~9-52 weeks; MN loss: 60% at 78 weeks | Mild motor coordination impairment |
| Vepr P56S (JAX 023360) | Gene targeted | Promoter: mVAPB | mVAPB: similar levels as WT (less protein in HOM than HET). WAPB translocated from ER to autophagosome | ND | Mild | Mild | ND | No final MN loss | Mild motor coordination impairment |

| (F) VCP mouse models |
|----------------------|
| HCP-R155H | Transgenic (p97/VCP-WT) | C57BL/6j | HVC | Inclusions: P | Ubiquitin: P | VCP: Ab | ND | P | ND | Earlier signs: ~24 weeks; no final MN loss | Mild motor coordination impairment |
| HCP-R155H | Transgenic | SJLxC57BL/6j | HVC | Inclusions: Ab | Ubiquitin: P | VCP: P | Mild | P | ND | Earlier signs: ~12 weeks; ~66 | Motor coordination impairment |
| HCP-A232E | Transgenic | SJLxC57BL/6j | HVC | Inclusions: Ab | Ubiquitin: P | VCP: P | Mild | P | ND | Earlier signs: ~12 weeks; ~66 | Motor coordination impairment |
| Vepr R195H (JAX 021999) | Gene targeted | Promoter: mVcp | 129SvEv/C57BL/6EJ (backcrossed >6× to be >98% C57BL/6) | mVcp | Inclusions: P | Ubiquitin: P | VCP: Ab | ND | ND | ND | Earlier signs: ~12 weeks; no final MN loss | Motor coordination impairment |
| Vepr R195H | Gene targeted | Promoter: mVcp | 129SvEv/C57BL/6EJ (backcrossed >6× to be >98% C57BL/6) | mVcp | Inclusions: P | Ubiquitin: P | VCP: Ab | P | ND | ND | Earlier signs: ~39 weeks; MN loss: 50% at ~66 weeks | Motor coordination impairment |
| Vepr R195H | Gene targeted | Promoter: mVcp | 129SvEv/C57BL/6EJ (backcrossed >6× to be >98% C57BL/6) | mVcp | Inclusions: P | Ubiquitin: P | VCP: Ab | P | P | P | Mild progressive weakness at ~69 weeks | Motor coordination impairment |

Ab, phenotype is stated as absent; BS, brain stem; CMV, cytomegalovirus; CNS, central nervous system; DG, dentate gyrus; DOX, doxycycline; FC, frontal cortex; GEM, Gemist cell bodies; GOF, gain of function; h (before gene/promoter/protein), human; HEM, hemizygous; HET, heterozygous; HOM, homozygous; LMN, lower motor neuron; LOF, loss of function; m (before gene/promoter/protein), mouse; MA, muscle atrophy; MD, muscle degeneration; MN, motor neuron; ND, phenotype has not been determined; NMJ, neuromuscular junction; Ntg, non-transgenic littermates; P, phenotype is present (see references listed in table); p, phosphorylated; SC, spinal cord; SG, stress granules; Tg, transgenic; Ub, ubiquitin; UMN, upper motor neuron; WT, wild type. All the phenotypes described on the genetic background indicated.
In contrast, only one of the published UBQLN2 transgenic lines, carrying the P497S mutation, which disturbs protosomal degradation, shows motor impairment, mild MN loss (20%) and cytoplasmic aggregates positive for ubiquitin and TDP-43 (Le et al., 2016) (Table 1D). The only mouse model expressing a mutated VAPB protein has a progressive phenotype resulting in ∼60% MN loss by 78 weeks of age (Aliaga et al., 2013) (Table 1E), whereas results are mixed for the VCP transgenic models (Table 1F). Despite the variability in phenotype presentation, transgenic mice remain a critical resource for understanding neurodegeneration but, like all mouse models, they have generic characteristics we need to take into account, as discussed below.

Site of insertion
Transgene DNA is usually microinjected into fertilised eggs and randomly inserts into the host mouse genome. This can lead to insertional mutagenesis from disrupting a host gene, producing an aberrant phenotype, which is why multiple founder lines from independent transgenic embryos are studied – to be confident that the common phenotypes arise from the transgene. Almost all transgenic lines in Table 1 do not have information on the insertion site, as is the case for the vast majority of transgenic models of neurodegenerative disease (Tosh et al., 2017; Goodwin et al., 2017). Fortunately, in SOD1G93A mice, the transgene insertion site does not disrupt a known gene (Srividstava et al., 2014; Achilli et al., 2005).

Transgene copy number and gene expression
Transgenic DNA tends to concatemerise as it inserts into the genome, leading to multiple copies of the exogenous sequence. This results in the overexpression of the protein of interest, often leading to accelerated phenotypes. Furthermore, a caveat to studying transgenic mice arises from the development of aberrant phenotypes due to overexpression. The SOD1G93A model used most commonly carries ∼25 copies of the human transgene, resulting in overexpression of the protein (Gurney et al., 1994; Shibata, 2001), with MN degeneration progressing rapidly; disease onset occurs at ~90 days and the humane endpoint occurs by ~130 days of age, depending on the genetic background of the mouse. However, transgenic mice expressing wild-type human SOD1 at a similar level to mice expressing the mutant transgene have neurological phenotypes likely arising from overexpression and not from mutation, including spinal cord vacuolation with early signs of paresis in one or more limbs (Jaarsma et al., 2000) and even MN loss (Graffito et al., 2013). Thus, the ideal controls for mutant transgenic mice are transgenic animals expressing the wild-type transgene at similar levels to the mutant mice to control for the effects of overexpression per se. However, the wild-type human SOD1 transgenic lines are not without problems. For example, transgene insertion sites have not been assessed, and although they develop phenotypes relevant to MN disease, these are more profound in some of the mutant SOD1 transgenic lines, such as the SOD1G93A model. Nevertheless, a large proportion of ALS studies in mutant transgenic mice do not use wild-type transgenic controls, and this is an option that should at least be considered for future work.

Some genes are highly dosage sensitive and a subtle deviation from the physiological levels leads to aberrant phenotypes, even when the protein product is wild type. Many of the RNA-binding proteins that cause ALS when mutated belong to this category, including TDP-43 and FUS (Table 1B,C). For example, transgenic mice overexpressing wild-type human TARDBP (from a Thy1.2 promoter) by 1.2× to 2× fold over the endogenous gene level have 25% MN loss with rare cytoplasmic inclusions containing TDP-43 (Wils et al., 2010). Overexpression of human wild-type FUS (under the mouse prion promoter) results in aggregation of human FUS protein and 60% loss of MNs in homozygous transgenic mice, leading to a more severe phenotype in homozygotes than in hemizygotes (Mitchell et al., 2013) (Table 1C). Indeed, RNA-binding proteins such as TDP-43 often control the expression levels of their own transcript through autoregulation. Therefore, when transgene expression levels of wild-type or mutant proteins rise above a threshold, the expression levels of the mouse endogenous transcripts are reduced, possibly contributing towards toxicity.

Furthermore, transgenes are often engineered to have exogenous promotors to ensure high levels of expression in the tissues of interest, but such ectopic expression can result in novel phenotypes. For example, two unrelated transgenic mouse lines overexpressing VCP with the R155H mutation, under the control of a muscle creatine kinase (mMCK) or a cytomegalovirus (CMV) promotor, have differences in the survival and presence of cytoplasmic aggregates containing VCP, and variability in the levels of motor impairment (Table 1F) (Weihl et al., 2007; Custer et al., 2010). Similarly, transgenic mice overexpressing mutant human TARDBP431S driven by the mouse prion promoter (the activity of which is strong in neurons, although it is also widely expressed in other cell types) unexpectedly die early from neurodegeneration in the gut rather than in MNs (Wegorzewska et al., 2009; Hatzipetros et al., 2014).

Finally, the transgene array may alter copy number at meiosis; thus, colonies need to be monitored constantly because the transgene’s copy number usually determines phenotype severity. For example, the Tg(SOD1*G93Adl)1Gur (SOD1G93Adl; also known as G1del) mice appear to have arisen from a deletion in the transgene array of a SOD1G93A mouse (http://jaxmice.jax.org/strain/002300.html). The resulting ‘low copy’ SOD1G93A transgenic mouse strain carries ∼8-10 copies of the human SOD1G93A transgene instead of the ∼25 in the progenitor line, and these ‘low copy’ animals develop paralysis between 24 and 34 weeks of age, considerably later than the ‘high copy’ progenitor line (Alexander et al., 2004; Acevedo-Arozena et al., 2011).

BAC transgenic mice
Most – but not all transgenic animals – have been made with the longest known complementary DNA (cDNA) sequence for the gene of interest; this is usually because of constraints on DNA insert size in the plasmid vectors used to subclone the transgenic constructs. To avoid this size limit and to generate mice carrying the full genomic architecture of a gene (which is particularly important in the case of C9ORF72-ALS, for which the mutation is intronic), researchers can generate transgenic mice with bacterial artificial chromosome (BAC) vectors, which can carry inserts of up to ∼200 kb. This approach was used to generate, for example, C9ORF72 (Balendra and Isaacs, 2018), TDP-43 (Swarup et al., 2011) and FUS (López-Erauskin et al., 2018) BAC transgenic mice. BACs randomly insert into the mouse genome, but generally with very low copy numbers (one to three copies), limiting the effects of overexpression of the gene of interest, although even subtle overexpression can alter the phenotype. As with all transgenics, there is the undesired possibility of insertion mutagenesis, in which integration of the transgene can disrupt an important gene.

Generic transgenic mouse features for ALS research
Until recently, transgenics were the fastest technology to obtain genetically modified mice, but this is changing as CRISPR/Cas9-based technologies develop. As discussed above, phenotypes can be rapid and severe in transgenic models because of expression of the
transgenic above endogenous levels. This is helpful for understanding the advanced stages of disease, which in the natural history of ALS is comparable to when most patients receive the diagnosis. Several transgenic models can have quantifiable, progressive loss of MNs severe enough to lead to profound locomotion defects and paralysis during the mouse lifespan (Table 1). These features made them the models of choice for pre-clinical studies and, until recently, almost all ALS therapeutics were solely tested on SOD1 transgenic models. This provides some explanation for the past failures of translating promising therapeutics from SOD1 transgenics to ALS patients, 98% of whom do not suffer from SOD1-ALS (Urushitani et al., 2007; Turner and Talbot, 2008; Riboldi et al., 2011; Vallarola et al., 2018).

### Mouse models with mutations at physiological levels in endogenous genes

#### Gene-targeted and ENU mutant strains

Mouse models of ALS can be generated by mutating mouse gene orthologues, to express the relevant protein at physiological levels. Here, we discuss the two key types of model with mutations in endogenous genes, produced from gene-targeting strategies or by random mutagenesis with the chemical N-ethyl-N-nitrosourea (ENU). We describe both as ‘physiological’ models in this article, as ‘knock-in’ (KI) is generally used for gene-targeted mice because it implies purposely engineering the mouse genome.

#### Gene-targeted models of ALS

Gene targeting entails introducing specific changes to a DNA sequence of interest. In mice, perhaps its most common use has been to create knockout (KO) animals in which the gene no longer functions, usually to help us understand the biology of individual genes. For example, the International Mouse Knockout program aims to functionally KO each mouse gene, providing phenotypic data for each KO line under the International Mouse Phenotyping program (Muñoz-Fuentes et al., 2018).

**Gene KOs**

Although most forms of ALS appear to be caused by toxic dominant GOF, KO models are an important resource as they can reveal not only critical gene function but also whether there is a loss-of-function (LOF) component to disease pathogenesis. For example, TDP-43 is usually depleted from the nucleus of MNs in TDP-43-ALS, presumably leading to a loss of nuclear TDP-43 function. Although homozygous TDP-43 KO mice are not viable, and heterozygous KO mice express a normal amount of TDP-43 protein due to its autoregulation, conditional TDP-43 KO lines and a transgenic line expressing small interfering RNA against TDP-43 develop MN degeneration (Kraemer et al., 2010), showing that acute TDP-43 LOF can be a driver of neurodegeneration. In SOD1-ALS, LOF can play a role in disease pathogenesis, as Sod1 KO mice develop a severe peripheral neuropathy, leading to denervation (Fischer et al., 2011) and SOD1-ALS patients generally have diminished SOD1 dismutase activity (Sacon et al., 2013).

#### KI mutations

Gene targeting has been used to insert specific mutations, usually (but not always; see Sharma et al., 2016; Gordon et al., 2019) into the endogenous mouse gene, with the aim of maintaining physiological expression levels of the (mutant) protein. This approach has been used thus far for Fus, Tardbp, Vaph, Vcp and Ubn1n2 mutations.

Classical gene targeting involves creating recombinant vectors for homologous recombination in mouse embryonic stem cells, which can be time-consuming and relatively expensive. However, CRISPR/Cas9 targeting in zygotes has made the production of gene-targeted mice – for example, such as two recently described strains recapitulating the human TARDBP Q331K mutation (Fratta et al., 2018; White et al., 2018) – considerably more efficient, faster and cheaper. Nevertheless, the possible off-target effects of this technology must be taken into account (Zhang et al., 2015).

One of the first KIs to model ALS was the VcpR155H strain (Badadani et al., 2010; Yin et al., 2012). These mice have age-dependent degeneration of ventral horn MNs with up to 50% MN loss, TDP-43-positive cytoplasmic inclusions, mitochondrial aggregation and progressive astrogliosis. These and other Vcp KO mice do not have rapidly progressive fatal ALS features, but they are important for understanding the onset of ALS (Table 1F).

Site-directed insertion of exogenous DNA into known ‘safe harbour’ sites in the genome, such as the Ros26 locus, also uses homologous recombination and is an alternative that avoids the random insertion mutagenesis of transgenic approaches. For example, TDP-43 KO mice have been generated by inserting the complete human TARDBP gene from a BAC, including introns and regulatory elements, into the Ros26 locus. These mice show low levels of human TDP-43 expression compared with their endogenous TDP-43, absence of inclusions or gliosis, and a mild age-dependent motor dysfunction, which may give insight into early-stage disease (Gordon et al., 2019).

### Genomic humanisation

Gene targeting, by homologous recombination or CRISPR/Cas9, enables us to make complex changes in mouse genes, including knocking in human genomic loci that carry important sequences for understanding disease and using these to completely replace the endogenous mouse genes. The FUSDelta14 KI heterozygous mice, expressing a partially humanised mutant FUS gene, carrying a splice acceptor site mutation that results in a frameshift that causes an aggressive form of ALS in humans, show progressive spinal MN loss, cytoplasmic mislocalisation of FUS and impaired lipid metabolism (Devoy et al., 2017) (Table 1C). An interesting avenue yet to be explored is the full humanisation of ALS genes. The biochemistry of human proteins, such as SOD1, is sometimes different from that of mouse orthologues, which could be relevant for disease modelling (Prudencio et al., 2009; Karch and Borchelt, 2010; Seetharaman et al., 2010). However, full humanisation of a gene in the context of the mouse genome remains technically challenging and may lead to artefactual results arising from altering the mouse cellular pathways. Thus, each model will have to be assessed carefully on a case-by-case basis and with wild-type human gene controls.

### Generic gene-targeted mutant mouse features for ALS research

Gene-targeted models express the gene of interest at physiological levels and more closely recapitulate the human ALS-causing mutations at both the genetic and biochemical levels. Together with transgenic models, they can also advance our understanding of disease pathomechanisms, as the technology allows the development of inducible or conditional models that dissect the timing and cell specificity of disease processes. For example, FUSANLS mice express a truncated FUS protein lacking the nuclear localisation signal (NLS), with floxed exons 13 and 14 followed by stop codons and a polyadenylation signal, allowing Cre-mediated reversal of the MN loss phenotype, giving new insight into the potential effects of ALS therapies at different disease stages (Seckic-Zahirovic et al., 2016) (Table 1C). However, although few ALS KI models have been
produced so far, as is clear from Table 1, the phenotypes of KI mice are often mild and progress slowly. For example, KI models of mutant \textit{Vapb} and \textit{Ubqln2} do not show strong, overt ALS features (Table 1D, F). Nevertheless, they are likely essential for understanding disease onset and the very earliest pathogenic mechanisms, and for developing important biomarkers.

**Random chemical mutagenesis**

Random mutagenesis of the mouse genome can give unexpected insight into human biology. Although other methods exist, such as the use of viral integration or radiation treatment, the majority of such mutant mouse models described in the literature come from the use of the powerful chemical mutagen ENU (Acevedo-Arozena et al., 2008). Typically, male mice are injected with ENU, left for several weeks until they start to produce mutant sperm and then mated to wild-type females. Their progeny, carrying point mutations, are assessed for phenotype in a forward genetics screen using wide-ranging tests, so that researchers interested in, for example, progressive locomotor mutants, may determine the causative point mutation and explore the underlying mechanism (Potter et al., 2016). This experimental design is also known as a ‘phenotype screen’. In parallel, sperm and DNA from male progeny are banked for ‘genotype screens’, in which researchers assay the DNA (usually tens of thousands of samples from a single large ENU program) for point mutations in their gene of interest. The corresponding stored sperm samples are then used for \textit{in vitro} fertilisation to (re)derive the relevant mouse line (Stottmann and Beier, 2014).

An informative example of an ENU mutant for ALS research was identified in a genotype screen of \textit{Sod1} within a DNA bank at the mouse facility at MRC Harwell in the UK (Table 1A). This strain, on a C57BL/6J background, carries a \textit{Sod1}^{D85G} mutation that is orthologous to the human \textit{SOD1}^{D85G} fALS mutation. Heterozygous animals only start to show mild locomotor effects at \textdegree88-weeks of age, but homozygous mutant mice have a striking phenotype that has allowed the separation of \textit{Sod1} LOF acting in the periphery and GOF effects in MN soma arising from mutant mouse Sod1 (Joyce et al., 2015).

**Generic ENU mutant mouse features for ALS research**

Depending on the dose of ENU, the progeny will have multiple mutations within their genome, not just in the gene of interest. Thus, these animals must be backcrossed for several generations to segregate away other mutations, and the flanking congenic region must be carefully assessed to avoid any confounding effects of nearby point mutations (Keays et al., 2007).

One of the advantages of working with ENU mice is the possibility of unexpected insights from novel mutations. However, a disadvantage is that a mutation identified in a genotype screen may not guarantee an aberrant phenotype. For example, our own group identified mouse samples with ENU-induced point mutations in \textit{Tardbp}, but extensive assessment of a rederived strain with a truncated TDP-43 (carrying a \textit{Tardbp}^{Q101X} mutation) revealed only limited phenotypes (Ricketts et al., 2014). Nevertheless, as our knowledge of the biochemistry and structure of ALS proteins improves, we can parse ENU mutants by protein domain to help decide which mice to rederive for study. Thus, in follow-up work, our group went on to investigate two more \textit{Tardbp} mutants, one carrying a mutation (M323K) within the low complexity domain (LCD), and the other with a mutation (F210I) in the second RNA-binding domain (RRM2) of TDP-43. The LCD mutation results in a progressive loss of spinal MNs, whereas the RRM2 mutation behaves as a LOF. Importantly for ALS research, transcriptomic analysis of these mice showed that C-terminal TDP-43 mutations lead to a TDP-43 gain-of-splicing function when mutations are expressed at physiological levels. This mutant TDP-43 GOF affects the splicing of a subset of genes not previously known to be controlled by TDP-43, leading to the appearance of new exon exclusion events called ‘skiptic exons’ that are, at least partially, also present in human TDP-43-ALS fibroblasts (Fratta et al., 2018) (Table 1B).

The TDP-43 ENU mutants highlight another property of ENU mutagenesis: using this method it is relatively straightforward to generate allelic series of animals that may help us dissect protein function.

**Transgenic compared with gene-targeted and ENU mouse models for ALS research**

Mice and humans are different animals, and we should not expect a single mouse model to fully recapitulate the entire trajectory of human neurodegenerative disease. We have summarised the key features of two generic types of mouse model – transgenic animals and those that express the gene/mutation of interest at physiological levels – looking at the ease of making each model, and at the types of phenotypes they develop, which usually vary largely because of different expression levels of the gene of interest.

For ALS alleles with dominant modes of inheritance, or where researchers wish to alter protein structure to help dissect function, we have a choice of the type of model to study, and each generic model has different applications (Table 1). Physiological models (gene-targeted and ENU models) have slower progression of phenotypes, which are less severe than in transgenic mice, presumably because proteins are not being overexpressed. However, they maintain correct spatial and temporal levels of expression, which is crucial to avoid the dose-dependent toxicity of some proteins, allowing the study of interactions between the gene/protein of interest and its partners within a pathway over the animal’s life span. Moreover, the late disease onset in these mice is useful for gaining insight into the pre-symptomatic stages, and to identify early biomarkers. However, slow phenotypes make these animals expensive to study, as statistically significant differences from their wild-type littermates may only arise after a year or more of life, incurring significant husbandry costs. Nevertheless, they provide a wide window onto early-stage disease processes. In contrast, transgenic animals tend to express strong phenotypes and clear MN loss, making them potentially more relevant to end-stage processes. These differences are exemplified by \textit{Vapb} and \textit{Ubqln2} KI models that have been valuable to study potentially impaired autophagy and proteasomal degradation mechanisms in ALS pathogenesis, but which do not develop the motor impairment or MN loss that can arise in their transgenic counterparts (Table 1D,E).

Mice carrying the TDP-43 Q331K fALS mutation (Table 1B) offer another comparison between gene-targeted KI and transgenic strains. \textit{Tardbp}^{Q331K} KIs model the toxic TDP-43 GOF, providing insight into the splicing alteration and the protein autoregulation impairment while reproducing aspects of frontotemporal dementia, although they do not show TDP-43 inclusions or MN loss (White et al., 2018; Fratta et al., 2018). In contrast, the TDP-43 Q331K transgenic line, with transgene expression driven by the mouse prion promoter, shows MN loss, muscle degeneration and neuromuscular junction loss with motor impairments, but only when the transgene is overexpressed above a threshold, confirming the dose-dependent toxic effects of TDP-43 expression (Arnold et al., 2013). Other conditional transgenic lines, such as...
hTDP-43ΔNLS mice devoid of the TDP-43 NLS, model the toxicity caused by cytoplasmic accumulation and nuclear depletion of TDP-43 (Izag et al., 2011) (Table 1B).

In summary, several different types of mouse model have been developed worldwide with the aim of reproducing ALS-like phenotypes for functional dissection (Table 1), and it is clear that having access to both transgenic and endogenous mice for each ALS gene could help build a comprehensive picture of the effects of different human ALS mutations.

Making use of all available ALS-related mouse strains
ALS is probably not a single disease, but arises sporadically and from mutations in a number of genes with varied functions. Mouse models can help us to unravel this complex picture by comparing phenotypes across ALS gene models (Fig. 1). For example, rNLS8 mice, a transgenic model expressing cytoplasmic TDP-43, showed that reactive microglia have an important role in rescuing MN degeneration caused by cytoplasmic TDP-43 expression (Spiller et al., 2018). This is in contrast to SOD1(G93A) transgenics, in which transplant of wild-type microglia significantly delays MN degeneration (Wu et al., 2006; Beers et al., 2006). These contrasting results highlight that there are specific disease trajectories in different mouse models, which is also likely the case in ALS patients. Therefore, moving forward, it will be critical to use a variety of models (mouse and other) to understand ALS pathogenesis more broadly, and there remains a need for more models for different ALS genes.

What is a good mouse model?
This brings us to a key question: what is a good mouse model? The short answer is the animal that is most informative for the underlying biology/disease under study. However, a more considered answer is that researchers must first define the features they are interested in, then chose the most appropriate model. Or better, choose different models to study the disease as broadly as possible. For example, are we looking for subtle, early molecular changes in spinal MNs, or are we interested in models with upper and lower MN death, or are we focusing on the role of glia?

There are many other factors to obtaining a useful mouse model and here we have discussed just one aspect – albeit the crucial one – of model design, i.e. how was the model generated. However, a mouse model’s phenotype also depends on the same factors as in humans, including sex and genetic background, which can have profound effects on how a mutation manifests. This is why we have been careful to include these descriptors in Table 1 (Bruijn et al., 2004; Heiman-Patterson et al., 2011; Mancuso et al., 2012; Nardo et al., 2013). Similarly, the environment can markedly affect disease manifestation; for example, environmental enrichment (such as running wheels and nesting material) can increase the life span and behavioural performance in SOD1-G93A mice (Sorrells et al., 2009). Conversely, single housing is a cause of stress in mice and can lead to decreased life span (Kallikoski et al., 2014), whereas good physical and social interactions positively affect animal welfare (Sundberg and Schofield, 2018).

Mouse models remain necessary for studying ALS, which is a collection of diseases that are not – as far as we know – cell autonomous and that involve different systems, including the immune system. Animal models provide a complex in vivo environment of tissues and cell–cell interactions, which are fundamental for the study of complex neurodegenerative diseases, such as ALS, in which the interactions between glia, MNs and muscle are likely necessary for disease development.

The final word
In gathering the information for this Review to populate the comprehensive Table 1, we found many inconsistencies in the literature describing new mouse lines. It is crucial that descriptions are as complete as possible to define the specific pathology of a model, including reporting the absence of important features, such as MN degeneration, and other negative results. The use of Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (Kilkenny et al., 2014) will improve reporting of mouse model phenotypes. In addition, it is critical to make new models freely available via The European Mouse Mutant Archive (EMMA) or The Jackson Laboratory (JAX).

The complexities of ALS are clearly exemplified by the wide array of phenotypes arising in the plethora of mouse models available. If anything, the past decades of research into ALS have shown us that to improve our understanding of disease pathogenesis, the community must embrace its complexities and work with different models. In the near future, integrating data from multiple sources, mouse and human, in vivo and in vitro, should allow us to build a more complete picture of health and disease states, over a lifetime. Ultimately, we must relate our findings back to humans, and cell, organoid and clinical models remain essential for cross-referencing and validating the findings from mouse studies.

Acknowledgements
We thank Dr Pietro Fratta and Dr Agnieszka Ule for critical reading of the manuscript.

Competing interests
The authors declare no competing or financial interests.

Funding
This work was supported by the Medical Research Council [MC_EX_MR/N501931/1 and MR/R005184/1 to E.M.C.F.], the Motor Neurone Disease Association [10/442 to E.M.C.F.] the Miguel Servet Programme of the Instituto de Salud Carlos III [CP15/00153 and P117/00244 to A.A.-J.] and the Collaborative Center for X-Linked Dystonia Parkinsonism [to E.M.C.F. and C.M.].

References
Acevedo-Arozena, A., Wells, S., Potter, P., Kelly, M., Cox, R. D. and Brown, S. D. M. (2008). ENU mutagenesis, a way forward to understand gene function. Annu. Rev. Genomics Hum. Genet. 9, 49-69.
Acevedo-Arozena, A., Kalmar, B., Essa, S., Ricketts, T., Joyce, P., Kent, R., Rowe, C., Parker, A., Gray, A., Hafefparast, M. et al. (2011). A comprehensive assessment of the SOD1(G93A) low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis. Model. Mech. 4, 686-700.
Achilli, F., Boyle, S., Kieran, D., Chia, R., Hafezparast, M., Martin, J. E., Schiavo, G., Greensmith, L., Bickmore, W. and Fisher, E. M. C. (2005). The SOD1 transgene in the G93A mouse model of amyotrophic lateral sclerosis lies on distal mouse chromosome 12. Amyotroph Lateral Scler. 6, 111-114.
Alexander, G. M., Erwin, K. L., Byers, N., Deitch, J. S., Augelli, B. J., Blankenhorn, E. P. and Heiman-Patterson, T. D. (2004). Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Mol. Brain Res. 130, 7-15.
Aliaga, L., Lai, C., Yu, J., Chub, N., Shim, H., Sun, L., Xie, C., Yang, W.-J., Lin, X., O’ Donovan, M. J. et al. (2013). Amyotrophic lateral sclerosis-related VAPB P56S mutation differentially affects the function and survival of corticospinal and spinal motor neurons. Hum. Mol. Genet. 22, 4293-4305.
Arnold, E. S., Ling, S.-C., Huelga, S. C., Lagier-Tourenne, C., Polymenidou, M., Ditsworth, D., Kordasiewicz, H. B., Mclalonis-Downes, M., Platoshyn, O., Parone, P. A. et al. (2013). ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl Acad. Sci. USA 110, E736-E745.
Badadani, M., Nalbandian, A., Watts, G. D., Vesa, J., Kitzawza, M., Su, H., Tanaja, J., Dec, E., Wallace, D. C., Mukherjee, J. et al. (2010). VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS ONE 5, e13183.
Balendra, R. and Isaacs, A. M. (2018). Cflorff2-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neuro. 14, 544-558.
Bannwarth, S., Ait-EI-Mkadem, S., Chaussenot, A., Genin, E. C., Lacas-Gervais, S., Fragaki, K., Berg-Alonso, L., Kageyama, Y., Serre, V., Moore,
D. G. et al. (2014). A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137, 2329-2345.

Beers, D. R., Henkel, J. S., Xiao, Q., Zha, W., Wang, J. Y., Yan, A. A., Siklos, L., McKenzer, S. R. and Appell, S. H. (2006). Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 103, 16021-16026.

Brenner, D., Yilmaz, R., Müller, K., Grehl, T., Petri, S., Meyer, T., Grosskreutz, J., Weydt, P., Ruf, W., Neuwirth, C. et al. (2018). Hot-spot KIF5A mutations cause familial ALS. Brain 141, 685-697.

Brown, R. H. and Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 162-172.

Bruzij, L. I., Mecher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Dejesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Beers, D. R., Henkel, J. S., Xiao, Q., Zhao, W., Wang, J., Yen, A. A., Siklos, L., Kurita, K., Kadoya, T., Aoki, M., Itoyama, Y. et al. (2014). Mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Arch. Neurol. 71, 1128-1135.

Chang-Hong, R., Wada, M., Koyama, S., Kimura, H., Arawaka, S., Kawanami, T., Chen, Y.-Z., Bennett, C. L., Huynh, H. M., Blair, I. P., Puls, I., Irobi, J., Dierick, I., Costa, J. and De Carvalho, M. (2015). TDP-43 mutations exhibit gain of splicing function and characteristics of SOD1 function and its implications for amyotrophic lateral sclerosis pathology. Neuroscientist 21, 519-529.

Chou, C.-C., Zhang, Y., Umoh, M. E., Vaughan, S. W., Lorenzini, I., Liu, F., Fratta, P., Sivakumar, P., Humphrey, J., Lo, K., Ricketts, T., Oliveira, H., Brito-Bruijn, L. I., Miller, T. M. and Cleveland, D. W. (2011). Motor neuron degeneration in mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Acta Neuropathol. 121, 688-697.

Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., 2006. Conversion to the amyotrophic lateral sclerosis mutant SOD1 in mice causes amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 103, 7142-7147.
Nalbandian, A., Llewellyn, K. J., Kitazawa, M., Yin, H. Z., Badanadi, M., Khanlou, N., Edwards, R., Nguyen, C., Mukherjee, J., Moazzafar, T. et al. (2012). The homozygous VCPR155H/R155H mouse model exhibits accelerated human VCP-associated disease pathology. PLoS ONE 7, e46308.

Nalbandian, A., Llewellyn, K. J., Badanadi, M., Yin, H. Z., Nguyen, C., Katheria, V., Watts, G., Mukherjee, J., Vesa, J., Caiozzo, V. et al. (2013). Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain 136, 3305-3332.

Nishimura, A. L., Mitne-Neto, M., Silva, H. C. A., Richieri-Costa, A., Middleton, S., Cascio, D., Kok, F., Oliveira, J. M. R., Gillingwater, T., Webb, J. et al. (2004). A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 75, 822-831.

Potter, P. K., Bowl, M. R., Jeyarajan, P., Wisby, L., Blease, A., Goldswothly, M. E., Simon, M. M., Greenaway, S., Michel, V., Barnard, A. et al. (2016). Novel gene function revealed by mouse mutagenesis screens for models of age-related disease. Nat. Commun. 7, 12444.

Pramataraova, A., Lagnânière, J., Roussel, J., Brisebois, K. and Rouleau, G. A. (2001). Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 21, 3369-3374.

Prudencio, M., Durazo, A., Whitelegge, J. P. and Borchelt, D. R. (2009). Modulation of mutant superoxide dismutase 1 aggregation by co-expression of wild-type enzyme. J. Neurochem. 108, 1009-1018.

Qiu, H., Lee, S., Shang, Y., Wang, W.-Y., Au, K. F., Kamiya, S., Barnarda, S. J., Finkbeiner, S., Lui, H., Carlton, C. E. et al. (2014). ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Invest. 124, 981-996.

Quarta, E., Bravi, R., Scambi, I., Mariotti, R. and Minciacchi, D. (2015). Increased anxiety-like behavior and selective learning impairments are concomitant to loss of hippocampal interneurons in the presymptomatic SOD1(G93A) ALS mouse model. J. Comp. Neurol. 523, 1622-1633.

Rentsch, A. E., Majounie, E., Walla, M., Simon-Sánchez, J. J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L. et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neurology 72, 257-268.

Riboldi, G., Nizzardo, M., Simone, C., Falcone, M., Bresolin, N., Comi, G. P. and Corti, S. (2011). ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development. Prog. Neurobiol. 95, 133-148.

Ricketts, T., Mcgoldrick, P., Fratta, P., De Oliveira, H. M., Kent, R., Phatak, V., Brandner, S., Blanco, G., Greensmith, L., Acevedo-Arozena, A. et al. (2014). A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing and causes limb-clasping and body tone defects. PLoS ONE 9, e85692.

Ripps, M. E., Huntley, G. W., Hof, P. R., Morrison, J. H. and Gordon, J. W. (1995). Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 92, 689-693.

Ripps, M. E., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Bentati, A., Donaldson, D., Goto, J., Oregan, J. P., Deng, H.-X. et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.

Saccon, R. A., Bunton-Stastynsh, R. K. A., Fisher, E. M. C. and Fratta, P. (2013). Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 136, 2342-2358.

Scekic-Zahirovic, J., Sendscheid, O., El Oussini, H., Jambeau, M., Sun, Y., Mersmann, S., Wagner, M., Dieterle, S., Sinner, J., Dirrig-Grosch, S. et al. (2016). Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. Acta Neuropathol. 133, 887-906.

Seetharaman, S. V., Taylor, A. B., Holloway, S. and Hart, P. J. (2010). Structures of mouse SOD1 and human/mouse SOD1 chimeras. Arch. Biochem. Biophys. 503, 183-190.

Semperton, C. F., Tang, A. A., Kulkarni, A., West, J., Brooks, M., Stubblefield, J. J., Regan, J. P., Deng, H.-X. et al. (2014). Activity-dependent FUS dysregulation disrupts synaptic homeostasis. Proc. Natl Acad. Sci. USA 111, E7695-E7703.

Shan, X., Chiang, P.-M., Price, D. L. and Wong, P. C. (2010). Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl Acad. Sci. USA 107, 16325-16330.

Sharma, A., Lysachkien, A. K., Lu, L., Nasrabyadi, S. E., Elmaleh, M., Moneghetsi, M., Neves, R. A. and Bajia, J. C. G. and Zende, S. A. et al. (2016). ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Proc. Natl Acad. Sci. USA. 107, 10465-10470.
